Both oocyte and ovarian tissue extraction and their subsequent cryopreservation are procedures used when women want to preserve their fertility. These procedures are performed when women are going to undergo medical treatments with possibly sterilizing side effects, or if they want to postpone pregnancy until a more mature age. They then use oocytes obtained at a young age and kept in cryopreservation.

The most common cause for the first scenario is the need to provide cancer treatments. 10% of neoplasias are detected in women under 45.

The need for chemotherapy, radiotherapy or bone marrow transplantation may have side effects on fertility, with premature loss of ovarian function and early menopause.

Therapeutic alternatives

In order to preserve the fertility of women affected by these treatments, two types of preventive intervention are being carried out, consisting of the extraction and cryopreservation of both oocytes and ovarian tissue.

The first option, oocyte cryopreservation, makes it possible to use them in future assisted reproduction procedures, such as in vitro fertilization, in which the oocytes are fertilized after being thawed and then implanted in the uterus for gestation.

This procedure must assume the risks and inconveniences of in vitro fertilization, as well as the risks associated with these techniques, such as prematurity, genetic defects and others, which we have previously reported.

The second option involves the extraction of ovarian tissue which is cryopreserved to be reimplanted in the woman after completing her treatment. This would allow her to recover ovarian function and become pregnant by natural means, avoiding the need to resort to assisted reproduction techniques.

Effectiveness of these techniques

As we published in 2019, the effectiveness of these techniques is measured by the live birth rate.

In the case of oocyte cryopreservation, this rate was initially 21.6% per embryo transfer with vitrified oocytes, but has increased over time.

Thus, in 2014, Grifo and Noyes reported a 57% birth rate per embryo transfer. Different reviews of studies showed a live birth rate of between 22.6 and 38.6%. This variation depends largely on the age of the woman at the time of oocyte retrieval. This rate drops by 13.4% among women over 40 years.

As for the second option, the pioneer in the extraction and transplantation of ovarian tissue was Dr. Jacques Donnez, professor and head of the chair of Gynecology at the Catholic University of Louvain.

In 2000, he cryopreserved the ovarian cortex in women with cervical carcinoma and ovarian tumors in order to reimplant it in the patients after thawing, with the aim of restoring endocrine function. Subsequently, in 2004, the first baby was born after an orthotopic transplant of cryopreserved ovarian tissue.

The technique of ovarian tissue transplantation for fertility preservation is currently performed in many centers in different countries, with data on more than 100 births following ovarian reimplantation.

In a study that Dr. Donnez’s group conducted in 2015, 111 cases of women who had undergone the procedure in Denmark, Belgium, Germany, Spain and Australia were analyzed. A pregnancy rate of 29% (32 patients) was obtained, with a delivery rate of 23%.

Two years later, in a series of 21 cases, the pregnancy rate rose to 41%. Up to 2022, more than 200 live births have been reported using cryopreservation and ovarian tissue autotransplantation (pregnancy rate >41%, live birth rate 21.6-30%).

In women who have undergone this technique and who suffer from some type of cancer such as leukemia, neuroblastoma or Burkitt’s lymphoma, there may be neoplastic cells in the biopsied tissue, and in such cases the process should not be completed.

According to a study by the same author, the risk is moderate for types of cancer such as stage 4 breast cancer, colon cancer, cervical adenocarcinoma, non-Hodgkin’s lymphoma and Ewing’s sarcoma. And for cases of stage 1 to 3 breast cancer, squamous cell carcinoma of the cervix, Hodgkin’s lymphoma and osteogenic carcinoma, the risk is low.

Ovarian tissue transplants can also be performed between patients, as has been the case with sisters who are not genetically identical, according to another study. The risks associated with this procedure caused this type of intervention to be stopped.

Finally, a final application of ovarian transplantation is related to the therapeutic approach to symptoms associated with menopause, as an alternative to hormone replacement therapies.

Ovarian tissue xenotransplantation

A recent study published in Human Reproduction provides an exhaustive review of numerous papers on the challenges and prospects of ovarian tissue transplantation.

In this case, they present ovarian tissue xenotransplantation, which consists of implanting tissue in a recipient of a murine species to support the follicular development of frozen-thawed ovarian samples.

The use of immunodeficient mice helps overcome some limitations of traditional transplantation methods by avoiding immune rejection, allowing the development and survival of the transplanted tissue.

Although immunodeficient mice offer a valuable model for xenotransplantation, they are not a perfect human replica. When comparing follicle populations before and after transplantation, significant changes in gene expression and epigenetic patterns were described.

As for immune rejection, it relies heavily on immunodeficient mice to overcome graft rejection by the recipient’s immune system. However, even immunodeficient mice retain some residual immune activity.

This may negatively affect long-term graft survival and potentially skew outcomes in terms of follicle growth and function.

Translating research findings from animal models into clinical applications presents challenges, such as species-specific differences and ethical considerations.

Although xenotransplantation allows for the evaluation of the safety and efficacy of ovarian tissue transplantation, alternative methods that minimize animal use and maximize clinical relevance are being sought.

Julio Tudela

Bioethics Observatory – Institute of Life Sciences

Catholic University of Valencia

Share This Story, Choose Your Platform!